Urologic Imaging

What Imaging Is Best for Surveillance of Stage I Nonseminoma Testicular Cancer?

·
What Imaging Is Best for Surveillance of Stage I Nonseminoma Testicular Cancer?

A 24-year-old male, six months post-orchiectomy for a stage IB nonseminoma germ cell tumor, presents for his scheduled follow-up. He feels well, has returned to work, and reports no new symptoms. His serum tumor markers—alpha-fetoprotein (AFP) and beta-human chorionic gonadotropin (β-hCG)—are within normal limits. You are tasked with ordering the appropriate surveillance imaging to monitor for occult recurrence. The goal is to detect potential metastatic disease early while minimizing harm from the surveillance protocol itself. This article details the American College of Radiology (ACR) recommended imaging workflow for this specific scenario, where `Radiography chest` is rated Usually Appropriate as a key component of the surveillance strategy.

Who Fits This Clinical Scenario for Nonseminoma Surveillance?

This guidance applies to a well-defined patient population: men diagnosed with pathologic stage IA or IB nonseminoma germ cell testicular cancer (NSGCT) who have undergone radical inguinal orchiectomy and have opted for active surveillance. A critical inclusion criterion is the absence of any clinical suspicion of recurrence. The patient should be asymptomatic, with physical examination and serum tumor markers showing no evidence of disease.

This workflow is distinct from several similar-sounding clinical situations that require different imaging approaches:

  • Pure Seminoma: Patients with stage I pure seminoma have a different natural history and pattern of recurrence. Their surveillance protocols, while similar, are addressed in a separate ACR variant.
  • Higher-Stage Disease (Stage II or III): Patients with known metastatic disease at diagnosis or after initial treatment follow more intensive imaging and treatment protocols, not the surveillance strategy outlined here.
  • Suspected Recurrence: If a patient presents with symptoms (e.g., back pain, cough, palpable mass) or has confirmed rising tumor markers, the clinical question shifts from surveillance to a diagnostic workup for recurrence. This is a separate ACR scenario that often warrants more aggressive imaging, such as PET/CT.

Applying this surveillance protocol to the wrong patient—for instance, one with rising markers—could dangerously delay the diagnosis of active disease.

What Are You Monitoring For During Nonseminoma Surveillance?

Active surveillance for stage I NSGCT is a strategy of monitoring for metastatic relapse, which occurs in approximately 30% of patients. The imaging protocol is designed to detect recurrence at its most common and earliest sites, allowing for timely and highly effective salvage therapy.

The primary targets of surveillance imaging are the retroperitoneal lymph nodes and the lungs. The retroperitoneum is the most common site of initial relapse for NSGCT, as lymphatic drainage from the testis flows directly to these nodes (specifically the para-aortic and paracaval chains). Detecting small-volume nodal disease before it becomes bulky or symptomatic is a key objective.

The second most common site of distant metastasis is the lungs. Hematogenous spread can lead to pulmonary nodules, which are often asymptomatic when small. Chest imaging is therefore a critical component of the surveillance regimen.

Less commonly, NSGCT can metastasize to the liver, bone, or brain. However, routine surveillance imaging of these sites is not recommended in asymptomatic, low-stage patients because the yield is extremely low. The focus remains on the high-probability locations—the retroperitoneum and lungs—where early detection has the greatest impact on outcomes.

Why Is a Multi-Modality Approach Recommended for This Presentation?

For the surveillance of stage I NSGCT, the ACR designates multiple imaging studies as Usually Appropriate, reflecting a strategy that balances detection efficacy with the long-term risks of repeated imaging, particularly radiation exposure in a young patient population. The core components are chest radiography for the lungs and cross-sectional imaging for the abdomen and pelvis.

Radiography chest is rated Usually Appropriate with a very low radiation dose (☢ <0.1 mSv). It serves as an effective, low-cost, and low-risk screening tool for pulmonary metastases. While less sensitive than CT for tiny nodules, its role is to detect clinically significant disease as part of a regular monitoring program.

For the retroperitoneum, both CT abdomen and pelvis with IV contrast and MRI abdomen and pelvis without and with IV contrast are rated Usually Appropriate.

  • CT with IV contrast provides excellent spatial resolution and is highly effective for identifying retroperitoneal lymphadenopathy. Its major drawback is the cumulative radiation dose (☢☢☢ 1-10 mSv per scan). Given that surveillance can last for five years or more, repeated CT scans can lead to a significant lifetime radiation burden.
  • MRI with and without IV contrast is an equally appropriate alternative that involves no ionizing radiation (O 0 mSv). It has demonstrated comparable accuracy to CT for detecting nodal recurrence. For this reason, many guidelines and institutional protocols now favor MRI to mitigate long-term radiation risks.

Alternative studies are rated lower for specific reasons. FDG-PET/CT, for example, is Usually Not Appropriate for routine surveillance in this setting. While useful for suspected recurrence, it has a high radiation dose (☢☢☢☢ 10-30 mSv) and a higher rate of false-positive findings for small-volume disease, leading to unnecessary anxiety and further workup. Similarly, US abdomen and retroperitoneum is Usually Not Appropriate because it is operator-dependent and bowel gas often obscures the deep retroperitoneal nodes, making it an unreliable tool for this purpose.

What’s Next After Surveillance Imaging? Downstream Workflow

The results of surveillance imaging, interpreted alongside serial tumor markers, guide the subsequent clinical pathway. The decision tree is generally straightforward.

  • Negative/Stable Findings: If chest radiography, abdominal/pelvic CT or MRI, and serum tumor markers are all negative or stable, the patient continues on the active surveillance protocol. The frequency of imaging and bloodwork typically decreases over time, following established guidelines (e.g., from the NCCN or EAU).
  • Positive Chest Radiograph: If a chest X-ray reveals a new or enlarging pulmonary nodule, the immediate next step is a CT chest without IV contrast. This is rated May be appropriate in the ACR criteria and is used to confirm the finding, characterize the nodule(s), and search for others not visible on the radiograph. A confirmed finding would trigger a consultation with oncology.
  • Positive Abdominal/Pelvic Imaging: If a CT or MRI of the abdomen and pelvis shows new or progressive retroperitoneal lymphadenopathy, this is highly suspicious for recurrence. The patient should be referred promptly to a urologic oncologist to discuss treatment options, which may include chemotherapy or a retroperitoneal lymph node dissection (RPLND).
  • Negative Imaging with Rising Tumor Markers: This is a challenging scenario that signifies micrometastatic or occult recurrence. The patient is no longer considered to be on surveillance but is now being worked up for a suspected recurrence. This is a different clinical scenario where more advanced imaging, such as an FDG-PET/CT, may become appropriate to locate the site of disease.

Pitfalls to Avoid (and When to Get Help)

Navigating long-term surveillance requires careful attention to detail to avoid common errors.

  • Incomplete Surveillance: Focusing only on the chest with X-rays while neglecting cross-sectional imaging of the retroperitoneum misses the most common site of relapse. A comprehensive protocol includes both.
  • Ignoring Cumulative Radiation: Repeatedly ordering CT scans without considering MRI as a radiation-free alternative can expose a young patient to unnecessary long-term risk. Discussing the rationale for MRI with the patient is a key part of shared decision-making.
  • Dismissing Marker Elevation: Never attribute a consistent rise in AFP or β-hCG to lab error without a thorough investigation. Rising markers in the setting of negative imaging often precede radiographically evident disease and require escalation.
  • Misinterpreting Post-Surgical Changes: Normal post-orchiectomy changes in the inguinal canal or scrotum on imaging can sometimes be mistaken for local recurrence. Familiarity with expected post-operative anatomy is crucial.

Any confirmed radiologic recurrence or definitive, sustained rise in tumor markers necessitates immediate referral to and collaboration with the patient’s multidisciplinary oncology team.

Related ACR Topics and Tools

This article covers one specific workflow within the broader topic of testicular cancer imaging. For a comprehensive overview of all related scenarios, from initial staging to post-treatment follow-up, please consult the parent guide. The following GigHz resources can also support your clinical decision-making:

Frequently Asked Questions

Why not just use CT for all surveillance since it’s more sensitive than chest X-ray?

The primary reason is to minimize cumulative radiation exposure. Patients with stage I testicular cancer are typically young and have an excellent prognosis, meaning they will undergo many years of surveillance. While CT is more sensitive, a chest CT delivers significantly more radiation than a chest X-ray. The strategy balances detecting clinically significant recurrence with the long-term risk of radiation-induced secondary malignancies. For the abdomen, MRI is an excellent radiation-free alternative to CT.

How often should surveillance imaging be performed for stage I nonseminoma?

The frequency of imaging is determined by national and international guidelines (such as NCCN or EAU) and is outside the scope of the ACR Appropriateness Criteria, which focuses on *what* study to order. Generally, imaging is most frequent in the first two years post-orchiectomy, when the risk of relapse is highest, and then the interval between scans gradually increases.

Is there a difference in surveillance imaging between stage IA and IB nonseminoma?

The ACR criteria group stage IA and IB together for this surveillance scenario, recommending the same imaging modalities. However, the *risk* of relapse is higher in stage IB (defined by the presence of lymphovascular invasion). This higher risk may influence the recommended *frequency* of surveillance imaging or the decision to offer adjuvant chemotherapy instead of surveillance, but the choice of imaging studies (the ‘what’) remains the same.

If a patient on surveillance has rising tumor markers but imaging is negative, what is the next step?

This situation indicates a recurrence that is not yet large enough to be seen on standard imaging. The patient’s clinical status changes from ‘surveillance’ to ‘suspected recurrence.’ This is a different clinical scenario where more sensitive imaging, such as an FDG-PET/CT scan, may become appropriate to locate the source of the tumor markers before starting systemic chemotherapy.

Should ultrasound of the remaining testicle be part of routine surveillance?

The ACR rates ‘US scrotum’ as *May be appropriate*. While the primary goal of surveillance is to detect distant metastases, there is a small risk of developing a second primary tumor in the contralateral testicle. Some guidelines recommend annual physical examination and patient self-examination. An ultrasound may be performed if there are palpable abnormalities or as part of an institutional protocol, but it is not a mandatory component for monitoring systemic recurrence.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 29, 2026